Same Indication

Montelukast vs Upadacitinib

Montelukast vs Upadacitinib: Overview

This comparison examines the pharmacological differences between Montelukast and Upadacitinib.

Mechanism of Action

Montelukast: Selective leukotriene D4 receptor antagonist.

Upadacitinib: Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.

Pharmacokinetics

Half-life: Montelukast — 2.7-5.5 hours; Upadacitinib — 9-14 hours.

Chemical Properties

Molecular Formula: Montelukast — C35H36ClNO3S; Upadacitinib — C17H19F3N6O.

Molecular Weight: Montelukast — 586.1800 g/mol; Upadacitinib — 380.3700 g/mol.

Type: Montelukast — Small molecule; Upadacitinib — Small molecule.